What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Volker Heinemann mostly deals with Internal medicine, Oncology, Colorectal cancer, Cetuximab and KRAS.
His Internal medicine research incorporates themes from Gastroenterology and Surgery.
His Oncology research includes elements of Clinical trial, Irinotecan, Metastasis, Hazard ratio and Bevacizumab.
His Colorectal cancer research includes themes of Clinical endpoint, Randomized controlled trial and Progression-free survival.
His Cetuximab research focuses on Targeted therapy and how it relates to Biomarker.
His KRAS study which covers Bioinformatics that intersects with RAS Mutation, Treatment outcome and Folinic acid.
His most cited work include:
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial (1000 citations)
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer (547 citations)
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (398 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Colorectal cancer, Cetuximab and Bevacizumab.
His work is dedicated to discovering how Internal medicine, Gastroenterology are connected with Pathology and other disciplines.
His Oncology research is multidisciplinary, incorporating perspectives in KRAS, Irinotecan, Surgery and Oxaliplatin.
His study in Colorectal cancer is interdisciplinary in nature, drawing from both Cancer research, Progression-free survival, Proportional hazards model, Hazard ratio and Single-nucleotide polymorphism.
He interconnects Cohort and First line in the investigation of issues within Bevacizumab.
His Pancreatic cancer research integrates issues from Biomarker and Erlotinib.
He most often published in these fields:
- Internal medicine (78.82%)
- Oncology (64.66%)
- Colorectal cancer (45.58%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (78.82%)
- Oncology (64.66%)
- Colorectal cancer (45.58%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Colorectal cancer, Cetuximab and Bevacizumab.
Internal medicine is closely attributed to Gastroenterology in his study.
In Oncology, he works on issues like FOLFOXIRI, which are connected to Wild type.
His work on KRAS as part of general Colorectal cancer study is frequently linked to In patient, bridging the gap between disciplines.
Volker Heinemann combines subjects such as First line and Epidermal growth factor receptor with his study of Bevacizumab.
In his research on the topic of Irinotecan, Fluorouracil is strongly related with Oxaliplatin.
Between 2017 and 2021, his most popular works were:
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (398 citations)
- Advances in cancer immunotherapy 2019 - latest trends. (141 citations)
- Advances in cancer immunotherapy 2019 - latest trends. (141 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Volker Heinemann focuses on Internal medicine, Oncology, Colorectal cancer, Bevacizumab and FOLFIRI.
His Internal medicine study frequently draws parallels with other fields, such as Gastroenterology.
His work deals with themes such as First line treatment, Cancer immunotherapy, Proportional hazards model, FOLFOXIRI and Panitumumab, which intersect with Oncology.
His Colorectal cancer research is multidisciplinary, incorporating elements of Fluorouracil, Progression-free survival, Cohort and Hazard ratio.
His Bevacizumab research includes elements of Cetuximab, Randomized controlled trial and MEDLINE.
His FOLFIRI study incorporates themes from Odds ratio and Targeted therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
